Profile | GDS2987 / GI_4503164-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 18.4 | 52 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | 8.1 | 27 |
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | 8.3 | 20 |
GSM215344 | HMVEC_atorvastatin_rep2 | 6.1 | 15 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 8.6 | 17 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 11.4 | 23 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 3.3 | 6 |
GSM215294 | HMVEC_SLx2119_rep1 | 8.2 | 29 |
GSM215295 | HMVEC_SLx2119_rep2 | 21.1 | 40 |
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 14.8 | 23 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 31.8 | 49 |
GSM215312 | PASMC_atorvastatin_rep2 | 14.2 | 23 |
GSM215313 | PASMC_atorvastatin_rep3 | 29.4 | 41 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 19.5 | 32 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 17.2 | 32 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 6.8 | 12 |
GSM215327 | PASMC_SLx2119_rep1 | 25.3 | 41 |
GSM215328 | PASMC_SLx2119_rep2 | 4.9 | 10 |
GSM215329 | PASMC_SLx2119_rep3 | 17.6 | 33 |
GSM215330 | Fibroblasts_vehicle_rep1 | 2.7 | 7 |
GSM215331 | Fibroblasts_vehicle_rep2 | 1.9 | 5 |
GSM215332 | Fibroblasts_vehicle_rep3 | 11.9 | 37 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 5 | 13 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 1.5 | 5 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 24.6 | 55 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 36.4 | 65 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 35.7 | 62 |